Cerebral Amyloid Angiopathy Cell Models for Research

Cerebral Amyloid Angiopathy (CAA) is a major cause of intracerebral hemorrhage and cognitive decline in the elderly. According to the World Health Organization (WHO), stroke, including hemorrhagic stroke, accounts for approximately 11% of total deaths worldwide, with CAA contributing to a significant proportion of lobar hemorrhages. The prevalence of CAA increases with age, affecting up to 50% of individuals over 80 years. Clinically, CAA presents with lobar intracerebral hemorrhage, transient focal neurological episodes, and progressive cognitive impairment. The 5-year survival after CAA-related hemorrhage is poor, with studies indicating a mortality rate of 30-50% within the first year. The National Cancer Institute (NCI) does not track CAA specifically, but data from the National Institute of Neurological Disorders and Stroke (NINDS) highlight the disease burden. Key risk factors include age, APOE ε4 allele, and Alzheimer's disease pathology.

CAA is an ideal model for studying protein misfolding, vascular biology, and neuroinflammation. Its subtypes, including sporadic and hereditary forms (e.g., Dutch, Icelandic), provide distinct genetic backgrounds for mechanistic studies. Public datasets such as the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Genotype-Tissue Expression (GTEx) project offer rich clinical and molecular data. Open questions include the role of APOE isoforms in vascular amyloid clearance, the contribution of pericytes and smooth muscle cells, and the interplay between CAA and Alzheimer's disease. Gene-edited cell models allow precise manipulation of key genes (APP, APOE, TREM2) to dissect these pathways.

CAA is driven by the accumulation of amyloid-beta (Aβ) peptides in the walls of cerebral blood vessels. Key pathways include:

• • Amyloid Precursor Protein (APP) Processing: Sequential cleavage by β-secretase (BACE1) and γ-secretase generates Aβ peptides. Mutations in APP or presenilins (PSEN1, PSEN2) alter Aβ production and aggregation.
• • Aβ Clearance: Impaired clearance via the blood-brain barrier (BBB), perivascular drainage, or enzymatic degradation (e.g., neprilysin, IDE) leads to vascular deposition.
• • APOE-Mediated Lipid Transport: APOE isoforms (ε2, ε3, ε4) differentially affect Aβ aggregation and clearance. APOE4 is the strongest genetic risk factor for CAA.
• • Neuroinflammation: Microglial activation and release of pro-inflammatory cytokines (TNF-α, IL-1β) contribute to vessel damage.

Data from ClinVar and COSMIC.

CAA involves several signaling networks:

• • MAPK/ERK Pathway: Activated by Aβ-induced oxidative stress, leading to endothelial dysfunction.
• • PI3K/AKT Pathway: Modulates cell survival and apoptosis in vascular smooth muscle cells.
• • NF-κB Pathway: Drives inflammatory gene expression in response to Aβ deposition.
• • TGF-β Signaling: Involved in fibrosis and vessel wall thickening.

Key nodes include APP, APOE, TREM2, and CD36.

Organoids, such as cerebral organoids, offer 3D models with multiple cell types, enabling study of cell-cell interactions in CAA.

• • Transgenic Mouse Models: Overexpressing mutant APP (e.g., Tg2576, APP23) develop CAA-like pathology.
• • APOE Knock-in Mice: Expressing human APOE isoforms to study their effects.
• • Zebrafish Models: Used for high-throughput drug screening.
• • PDX Models: Not commonly used for CAA, but xenografts of human brain endothelial cells can be employed.

CRISPR-Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications. For CAA, examples include:

• • APP Knockout Cell Lines: To study the role of APP in Aβ production.
• • APOE4 Knock-in Cell Lines: To model the high-risk allele in endothelial cells.
• • TREM2 Knockout Cell Lines: To investigate microglial function.

These sequence-verified models are commercially available and accelerate research by providing consistent, reproducible systems. They are essential for target validation and drug screening.

Knockout and knock-in lines allow functional validation of genes implicated in CAA. For example, knocking out APOE in endothelial cells can reveal its role in Aβ clearance. Similarly, introducing the APOE4 allele can model the increased risk. These models help identify novel therapeutic targets.

Isogenic pairs (e.g., wild-type vs. APOE4 knock-in) are used to screen compounds that modulate Aβ aggregation or clearance. Resistance mechanisms to therapies can be studied by exposing cells to drugs and selecting for resistant clones.

CRISPR-based synthetic lethality screens can identify genes that, when silenced, kill cells with specific mutations (e.g., APOE4). This approach can uncover novel biomarkers and therapeutic vulnerabilities.